242 related articles for article (PubMed ID: 29723921)
1. De novo belatacept in clinical vascularized composite allotransplantation.
Cendales LC; Ruch DS; Cardones AR; Potter G; Dooley J; Dore D; Orr J; Ruskin G; Song M; Chen DF; Selim MA; Kirk AD
Am J Transplant; 2018 Jul; 18(7):1804-1809. PubMed ID: 29723921
[TBL] [Abstract][Full Text] [Related]
2. Benefits and limitations of belatacept in 4 hand-transplanted patients.
Grahammer J; Weissenbacher A; Zelger BG; Zelger B; Boesmueller C; Ninkovic M; Mühlbacher A; Peschel I; Brandacher G; Öfner D; Schneeberger S
Am J Transplant; 2017 Dec; 17(12):3228-3235. PubMed ID: 28742936
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report.
Cendales L; Bray R; Gebel H; Brewster L; Elbein R; Farthing D; Song M; Parker D; Stillman A; Pearson T; Kirk AD
Am J Transplant; 2015 Aug; 15(8):2250-5. PubMed ID: 25773260
[TBL] [Abstract][Full Text] [Related]
4. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
[TBL] [Abstract][Full Text] [Related]
5. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
6. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
7. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
8. Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States.
Karadkhele G; Duneton C; Garro R; Badell IR; Pearson TC; Larsen CP; Hogan J
Clin Transplant; 2022 Mar; 36(3):e14531. PubMed ID: 34757651
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
10. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
11. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
[TBL] [Abstract][Full Text] [Related]
12. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
13. Costimulation Blockade in Vascularized Composite Allotransplantation.
Giannis D; Moris D; Cendales LC
Front Immunol; 2020; 11():544186. PubMed ID: 33042138
[TBL] [Abstract][Full Text] [Related]
14. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
16. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
Woodle ES; Kaufman DB; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Am J Transplant; 2020 Apr; 20(4):1039-1055. PubMed ID: 31680394
[TBL] [Abstract][Full Text] [Related]
17. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
18. De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient.
Cohen EA; Mulligan D; Kulkarni S; Tichy EM
Am J Transplant; 2016 Sep; 16(9):2753-7. PubMed ID: 27137752
[TBL] [Abstract][Full Text] [Related]
19. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
Everly MJ; Roberts M; Townsend R; Bray RA; Gebel HM
Am J Transplant; 2018 Sep; 18(9):2305-2313. PubMed ID: 29767445
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation.
Anderson DJ; Lo DJ; Leopardi F; Song M; Strobert EA; Jenkins JB; Larsen CP; Kirk AD
Clin Transplant; 2019 Jun; 33(6):e13568. PubMed ID: 31006146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
